“Despite advances in obesity research, there remains a critical unmet need for effective therapies that address the underlying genetic causes. These data lay the groundwork for bringing new hope ...

Due to the close relationship between obesity and the onset of diabetes, understanding this pathway in depth could help develop new ways to treat ... serves as the first trigger of β-cell ...

Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity ... designed based on preclinical and human genetic data that strongly suggest GIPR ...

Researchers at the Paul Scherrer Institute PSI have developed an AI that could open up a new, cost-effective approach to identifying genetic perturbation ... each other and trigger biochemical ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio ...